240-patient Phase 2 trial finds OKYO Pharma's OK-101 ophthalmic solution effective for dry eye disease, reducing ocular pain and improving tear film break-up time.
OKYO Pharma's OK-101 (0.05%) ophthalmic solution showed promising results in a 240-patient Phase 2 trial for dry eye disease. The treatment demonstrated a significant and durable reduction in ocular pain, with statistically significant improvements in tear film break-up time and other symptoms. OK-101's exceptional drop comfort and favorable adverse event profile support its Phase 3 development.
March 22, 2024
6 Articles